Pharmaceutical manufacturer Eli Lilly and Company on Wednesday announced it would reduce the price of its most commonly prescribed insulins by 70% and expand its Insulin Value Program that limits patients’ monthly out-of-pocket costs to $35 or less.
Read MoreEli Lilly Cuts Insulin Prices by 70 Percent, Caps Monthly Out-of-Pocket Costs at $35
